HIF1A and neoplasm: Importantly, there were no differences in the expression levels of the angiogenic factors Hif1α and Vegfα between control and ruxolitinib treatment groups (Figs. S4e and S4f), suggesting that impairment of tumor cell proliferation is responsible for the reduced tumor burden upon ruxolitinib treatment in these models.